Clinical Trial

Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated February 17, 2025 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
ETP-ALL is a subtype of T-cell acute lymphoblastic leukemia (T-ALL) with poor outcomes and prognosis. Effective induction therapy is crucial in improving the treatment effect. Based on our laboratory research and clinical practice, the venetoclax plus HAG regimen shows promising efficacy in treating ETP-ALL. Therefore, we plan to conduct a prospective, multicenter Phase III clinical study to evaluate the efficacy of the venetoclax plus HAG regimen in treating newly diagnosed ETP-ALL patients.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-04-08; most recent amendment 2025-02-13.
Status change: Not Yet Recruiting → Recruiting 2024-04-25
Trial Details
NCT Number NCT06361329
Lead Sponsor First Affiliated Hospital of Zhejiang University
Conditions ETP-ALL
Enrollment 81 participants
Start Date 2024-04-03
Primary Completion 2026-03-31 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-02-17